公开(公告)号：US12102668B2

公开(公告)日：2024-10-01

申请号：US16298112

申请日：2019-03-11

Applicant: RegenLab USA LLC

Inventor： Antoine Turzi

IPC: A61K36/16 ,  A61K8/98 ,  A61K31/728 ,  A61K35/14 ,  A61K35/15 ,  A61K35/16 ,  A61K35/17 ,  A61K35/18 ,  A61K35/19 ,  A61K38/36 ,  A61K38/48 ,  A61L26/00 ,  A61M1/02 ,  A61M5/19 ,  A61Q19/08

CPC classification number: A61K38/4833 ,  A61K8/981 ,  A61K8/983 ,  A61K31/728 ,  A61K35/14 ,  A61K35/15 ,  A61K35/16 ,  A61K35/17 ,  A61K35/18 ,  A61K35/19 ,  A61K38/363 ,  A61L26/0057 ,  A61L26/0066 ,  A61M1/0209 ,  A61M1/029 ,  A61M5/19 ,  A61Q19/08 ,  C12Y304/21005 ,  A61L2300/30 ,  A61L2300/412 ,  A61M2202/0425 ,  A61M2202/0427 ,  A61K35/16 ,  A61K2300/00 ,  A61K35/14 ,  A61K2300/00 ,  A61K35/19 ,  A61K2300/00 ,  A61K35/17 ,  A61K2300/00 ,  A61K35/15 ,  A61K2300/00 ,  A61K38/363 ,  A61K2300/00 ,  A61K35/18 ,  A61K2300/00 ,  A61K31/728 ,  A61K2300/00

Abstract: The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof.

公开(公告)号：US11911448B2

公开(公告)日：2024-02-27

申请号：US16535398

申请日：2019-08-08

Applicant: Omrix Biopharmaceuticals Ltd.

Inventor： Erez Ilan ,  Omri Faingold ,  Sivan Doron

IPC: A61K47/10 ,  A61K38/48 ,  A61K47/02 ,  A61P7/04 ,  A61K47/42

CPC classification number: A61K38/4833 ,  A61K47/02 ,  A61K47/10 ,  A61K47/42 ,  A61P7/04 ,  C12Y304/21005

Abstract: The present invention provides methods for large scale preparation of sterile stable liquid thrombin composition comprised of glycerol; stable liquid thrombin compositions; and hemostatic composition and kits. The present invention further provides hemostatic compositions comprised of liquid thrombin, glycerol and gelatin. Further provided herein is a method for the large-scale production of a sterile liquid thrombin composition comprised of glycerol.

公开(公告)号：US20230158119A1

公开(公告)日：2023-05-25

申请号：US18096087

申请日：2023-01-12

Applicant: Omrix Biopharmaceuticals Ltd.

Inventor： INBAR GAHALI-SASS ,  ISRAEL NUR ,  EREZ ILAN ,  RONEN EAVRI

IPC: A61K38/36 ,  A61K38/48 ,  A61P41/00 ,  A61K38/37 ,  A61K9/08 ,  A61P7/04 ,  A61K33/06 ,  A61K38/38

CPC classification number: A61K38/363 ,  A61K38/4833 ,  A61P41/00 ,  A61K38/37 ,  A61K9/08 ,  C12Y304/21005 ,  A61P7/04 ,  A61K33/06 ,  A61K38/366 ,  A61K38/38

Abstract: Disclosed herein is an anti-adhesion kit comprised of: (i) a fibrinogen solution component comprising: fibrinogen at a concentration of about 5 to 25 mg/ml; and free calcium ions at a concentration ranging from 0.1 μM to 1 mM; and (ii) a thrombin component containing thrombin. Further disclosed is an anti-adhesion kit comprised of: (i) a fibrinogen solution component containing fibrinogen at a concentration of 8% to 25% of total protein by weight, and optionally free calcium ions at a concentration ranging from 0.1 μM to 1 mM; wherein a total protein concentration ranges from about 80 to 120 mg/ml; and (ii) a thrombin component containing thrombin. Methods of using the kits e.g., to provide anti-adhesion curable compositions are also disclosed.

公开(公告)号：US20190233503A1

公开(公告)日：2019-08-01

申请号：US16379559

申请日：2019-04-09

Applicant: Kieu Hoang

Inventor： Kieu Hoang

IPC: C07K16/06 ,  C07K1/18 ,  C07K1/34 ,  C07K1/14 ,  C07K16/10 ,  C07K1/36

CPC classification number: C07K16/065 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/36 ,  A61K38/4833 ,  A61K38/4846 ,  A61K2039/54 ,  C07K1/145 ,  C07K1/18 ,  C07K1/34 ,  C07K1/36 ,  C07K16/109 ,  C07K2317/10 ,  C07K2317/76 ,  C12N9/6429 ,  C12Y304/21005 ,  C12Y304/21006 ,  C12Y304/21021 ,  C12Y304/21022

Abstract: The present subject matter is directed to a method of manufacturing and purifying an intravenous injection of prothrombin complex concentration (PCC) from plasma Fraction III and a method of manufacturing and purifying an intravenous injection of non-PCC from plasma Fraction IV. The intravenous injection of PCC and non-PCC obtained from the method can be administered to a patient in need thereof for stopping replication, killing and preventing HIV-1 and HIV-2 in a patient.

公开(公告)号：US20190231922A1

公开(公告)日：2019-08-01

申请号：US16272302

申请日：2019-02-11

Applicant: Baxter International Inc. ,  Baxter Healthcare SA

Inventor： Andreas Goessl ,  Atsushi Edward Osawa ,  Cary J. Reich

IPC: A61L24/04 ,  A61L24/10 ,  A61K9/16 ,  A61L24/00 ,  B65B55/02 ,  B65B5/12 ,  B65B3/00 ,  A61K38/48 ,  A61K9/19 ,  A61K9/00 ,  A61K38/39

CPC classification number: A61L24/043 ,  A61K9/0014 ,  A61K9/1658 ,  A61K9/19 ,  A61K38/39 ,  A61K38/4833 ,  A61L24/0015 ,  A61L24/10 ,  A61L24/106 ,  A61L2300/418 ,  A61L2300/802 ,  A61L2400/04 ,  A61L2400/06 ,  B65B3/003 ,  B65B5/12 ,  B65B55/02 ,  C12Y304/21005 ,  Y10T428/13

Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) providing said first component and said second component in a combined form in a final container, c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container, c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container, d) finishing the final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.

公开(公告)号：US20190192667A1

公开(公告)日：2019-06-27

申请号：US16291854

申请日：2019-03-04

Applicant: Baxter International Inc.

Inventor： Richard I. Senderoff ,  Jeffrey D. Meyer ,  Emily N. Rollins ,  Steven D. Hughes ,  Richard M. Garcia ,  Paul D. Bishop ,  Gerald W. Lasser

IPC: A61K47/42 ,  A61K47/26 ,  A61K47/10 ,  A61K38/48 ,  A61K9/06 ,  A61K47/32 ,  A61K47/38 ,  A61K9/00

CPC classification number: A61K47/42 ,  A61K9/0024 ,  A61K9/06 ,  A61K38/4833 ,  A61K47/10 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  C12Y304/21005 ,  Y10T428/2982

Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.

公开(公告)号：US10080770B2

公开(公告)日：2018-09-25

申请号：US15720859

申请日：2017-09-29

Applicant: RegenLab USA LLC

Inventor： Antoine Turzi ,  Donald Francois Du Toit

IPC: A61L24/00 ,  A61L24/10 ,  A61L26/00 ,  A61M1/36 ,  A61K35/14 ,  A61K35/16 ,  A61K38/36 ,  A61K35/18 ,  A61K35/36 ,  A61Q19/00 ,  A61K8/98 ,  A61K35/19 ,  A61K35/15 ,  A61K35/28 ,  A61K35/30 ,  A61K35/32 ,  A61K35/34 ,  A61K35/35 ,  A61K35/38 ,  A61K35/39 ,  A61K35/51 ,  A61K38/48 ,  A61L27/36 ,  A61L27/38 ,  A61Q19/08

CPC classification number: A61K35/19 ,  A61K8/981 ,  A61K8/983 ,  A61K35/14 ,  A61K35/15 ,  A61K35/16 ,  A61K35/18 ,  A61K35/28 ,  A61K35/30 ,  A61K35/32 ,  A61K35/34 ,  A61K35/35 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/51 ,  A61K38/363 ,  A61K38/4833 ,  A61K2300/00 ,  A61K2800/87 ,  A61L24/0005 ,  A61L24/106 ,  A61L26/0042 ,  A61L26/0057 ,  A61L27/3691 ,  A61L27/3886 ,  A61L2430/02 ,  A61M1/3693 ,  A61M2202/0427 ,  A61Q19/00 ,  A61Q19/08 ,  C12Y304/21005

Abstract: The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.

公开(公告)号：US20180153969A1

公开(公告)日：2018-06-07

申请号：US15886699

申请日：2018-02-01

Applicant: Antoine Turzi

Inventor： Antoine Turzi

IPC: A61K38/48 ,  A61K8/98 ,  A61K31/728 ,  A61M5/19 ,  A61K38/36 ,  A61K35/17 ,  A61K35/19 ,  A61K35/14 ,  A61K35/16 ,  A61K35/18 ,  A61K35/15 ,  A61L26/00 ,  A61Q19/08 ,  A61M1/02

CPC classification number: A61K38/4833 ,  A61K8/981 ,  A61K8/983 ,  A61K31/728 ,  A61K35/14 ,  A61K35/15 ,  A61K35/16 ,  A61K35/17 ,  A61K35/18 ,  A61K35/19 ,  A61K38/363 ,  A61L26/0057 ,  A61L26/0066 ,  A61L2300/30 ,  A61L2300/412 ,  A61M1/0209 ,  A61M1/029 ,  A61M5/19 ,  A61M2202/0425 ,  A61M2202/0427 ,  A61Q19/08 ,  C12Y304/21005 ,  A61K2300/00

Abstract: The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof.

公开(公告)号：US09932388B2

公开(公告)日：2018-04-03

申请号：US14883574

申请日：2015-10-14

Applicant: HEMARUS THERAPEUTICS LIMITED

Inventor： Ashok Kumar Nuvula ,  Mitali Samaddar ,  Neelima Vadde ,  Zinia Chakraborty ,  Swapna Sagar Duggineni ,  Uma Devi Komath

IPC: C07K14/75 ,  A61L24/10 ,  A61L24/02 ,  C12N9/74

CPC classification number: C07K14/75 ,  A61L24/02 ,  A61L24/106 ,  A61L24/108 ,  C12N9/6429 ,  C12Y304/21005

Abstract: The present invention relates to a chromatographic process for obtaining purified fibrinogen and thrombin from human plasma. The purified fibrinogen and thrombin preparations contain plasminogen in amounts less than 1 ug/mL. The low levels of plasminogen eliminates use of a proteolytic inhibitor, such as aprotinin in fibrin sealant kits which are used for human therapeutic applications.

公开(公告)号：US20180087039A1

公开(公告)日：2018-03-29

申请号：US15715977

申请日：2017-09-26

Applicant: Northwestern University

Inventor： Melina R. Kibbe ,  Samuel I. Stupp

IPC: C12N9/64 ,  A61K47/64 ,  A61K38/48 ,  A61K9/00 ,  A61K45/06

CPC classification number: C12N9/6437 ,  A61K9/0019 ,  A61K9/70 ,  A61K38/4833 ,  A61K45/06 ,  A61K47/542 ,  A61K47/64 ,  A61K47/69 ,  C12Y304/21005 ,  C12Y304/21006 ,  C12Y304/21021

Abstract: Provided herein are tissue factor (TF)-targeted nanofibers and methods of treating hemorrhage in a subject therewith. In particular, peptide amphiphiles (PAs) are provided that comprise a TF-targeting peptide sequence and self-assemble under aqueous conditions into PA nanofibers displaying the TF-targeting sequence on the exterior of the nanofiber.